Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Steglatro for Adults with T2D

Pfizer news release; 2017 Dec 22

FDA has approved Steglatro (ertugliflozin) oral tablets for the treatment of adults with type 2 diabetes. The approval was granted to Merck and Pfizer Inc.

Indications: Steglatro is a sodium glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Dosage and administration: Recommended starting dose is 5 mg once daily, taken in the morning, with or without food. Increase dose to 15 mg once daily in those tolerating Steglatro and needing additional glycemic control. Assess renal function before initiating Steglatro and periodically thereafter.

Adverse reactions: The most common adverse reactions associated with Steglatro (incidence ≤5%) were female genital mycotic infections.

Citation:

FDA approves SGLT2 inhibitor Steglatro (ertugliflozin) for adults with type 2 diabetes. [news release]. Merck, Pfizer: December 22, 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209803s000lbl.pdf. Accessed December 24, 2017.

This Week's Must Reads

ACS Recommends CRC Screening at Age 45, CA Cancer J Clin; ePub 2018 May 30; Wolf, et al

ACP Position on Women’s Health Challenges, Ann Intern Med; ePub 2018 May 29; Daniel, et al

Lung Cancer Incidence in Young Men & Women, N Engl J Med; 2018 May 24; Jemal, et al

Aspirin Benefit in Adverse Pregnancy Outcomes, Hypertension; ePub 2018 May 25; Hauspurg, et al

Monitoring NT-proBNP in Patients with Diabetes, Diabetes Care; ePub 2018 May 30; Jarolim, et al

Must Reads in Diabetes

Monitoring NT-proBNP in Patients with Diabetes, Diabetes Care; ePub 2018 May 30; Jarolim, et al

Trends in Diabetes-Related Mortality in the US, Lancet; ePub 2018 May 18; Gregg, Cheng, et al

Plasma Methylglyoxal Levels & Diabetic CVD, Diabetes Care; ePub 2018 May 21; Hanssen, et al

Risk of T2D Among Lesbian and Bisexual Women, Diabetes Care; ePub 2018 May 2; Corliss, et al

Prevalence of Diabetes in the US by Type, MMWR; 2018 Mar 30; Bullard, Cowie, et al